While GIP was not previously considered an attractive drug target, recent studies have started re-evaluating GIP’s therapeutic potential and have proposed GIP receptor signalling and dual GIP/GLP-1 receptor agonists as a novel means to reduce insulin resistance among T2D cases who have likely developed GIP resistance [46–48]. The gene discussed is GIP; the disease is type 2 diabetes mellitus.